Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07115953

Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension

The purpose of the SPYRAL SWYFT sub-study is to evaluate whether renal denervation with the Symplicity Spyral system performed in the main and first order branch renal arteries yields a shorter procedure time and is as effective in reducing blood pressure than the procedural approach used in the SPYRAL HTN-ON MED and SPYRAL PIVOTAL - SPYRAL HTN-OFF MED clinical studies in an uncontrolled hypertensive population.

Recruiting

Interested in participating?

Request Info

Key information

About this study

SPYRAL SWYFT will evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system to determine whether renal denervation performed in the main and first order branch renal arteries yields a shorter procedure time and is as effective in reducing blood pressure than the procedural approach used in the SPYRAL HTN-ON MED and SPYRAL PIVOTAL - SPYRAL HTN-OFF MED clinical studies (where all accessible renal arterial vessels between 3 and 8 mm in diameter including accessory, branch and main renal arteries (outside the kidney parenchyma) were targeted for ablation).

SPYRAL SWYFT study is conducted under the overarching SPYRAL AFFIRM protocol (NCT05198674), focused on EU and APAC regions.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individual is diagnosed with hypertension and has a baseline office systolic blood pressure ≥140 mmHg
  • Individual has a baseline office diastolic blood pressure ≥ 90 mmHg
  • Individual has an average systolic baseline home blood pressure ≥135 mmHg (with ≥7 days of valid pre-procedure measurements)
  • Individual has a valid 24-hour Ambulatory Blood Pressure Measurement at baseline

Exclusion criteria

  • Individual lacks appropriate renal artery anatomy
  • Individual has undergone prior renal denervation
  • Individual has a documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement
  • Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea
  • Individual has an estimated glomerular filtration rate (eGFR) of <45 mL/min/1.73m2
  • Individual has one or more episode(s) of orthostatic hypotension
  • Individual is pregnant, nursing or planning to become pregnant
  • Individual has documented primary pulmonary hypertension
  • Individual has documented type 1 diabetes mellitus or poorly-controlled type 2 diabetes mellitus with glycosylated hemoglobin greater than 8.0%

Treatment and study plan

Symplicity Spyral™ multi-electrode renal denervation system

Device

After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.

Other names: Renal Angiography, Renal Denervation

Primary outcomes

  1. Procedure time

    Time frame: Procedure

    Procedure time will be compared to the SPYRAL HTN-ON MED and SPYRAL PIVOTAL - SPYRAL HTN-OFF MED procedure times.

  2. Office Systolic Blood Pressure Change

    Time frame: 6 months

    Office Systolic Blood Pressure (OSBP) change from baseline to 6 months will be compared to the SPYRAL HTN-ON MED and SPYRAL PIVOTAL - SPYRAL HTN-OFF MED study efficacy endpoints using a propensity score stratified baseline blood pressure adjusted analysis at 3 months (OFF MED) and 6 months (ON MED).

Secondary outcomes

  1. Office Systolic Blood Pressure change

    Time frame: From baseline to 3, 6, 12, 24, and 36 months post-procedure

  2. Home Blood Pressure change

    Time frame: From baseline to 3, 6, 12, 24, and 36 months post-procedure

  3. Change in blood pressure as measured by 24-hour ABPM

    Time frame: From baseline to 3, 6, 12, 24, and 36 months post-procedure

  4. Percent of subjects achieving blood pressure control as measured by OBP, HBP and ABPM

    Time frame: From baseline to 3, 6, 12, 24, and 36 months post-procedure

  5. Time subject's blood pressure is controlled

    Time frame: Procedure to 36 months post-procedure

  6. Change in number of anti-hypertensive medications taken from baseline

    Time frame: From baseline to 3, 6, 12, 24, and 36 months post-procedure

  7. Change from baseline in hypertension health status score

    Time frame: From baseline to 3, 6, 12, 24, and 36 months post-procedure. A higher score means a better outcome.

  8. Evaluate factors influencing blood pressure response to renal denervation

    Time frame: From baseline to 3, 6, 12, 24, and 36 months post-procedure

  9. Evaluation of slope of eGFR

    Time frame: From baseline to 3, 6, 12, 24, and 36 months post-procedure

  10. Incidence of safety events, including major adverse events

    Time frame: From baseline to 3, 6, 12, 24, and 36 months post-procedure

Study contacts

Contact information is provided by the study sponsor or research team.

Carly Loudoun

CONTACT

[email protected]

+31 43 356 6566

Kelsey Anderson

CONTACT

[email protected]

651 247 5268

Sponsors and collaborators

Lead sponsor

Medtronic Vascular

Industry

Registry information

Official study title

Sub-study of SPYRAL AFFIRM: Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT)

Acronym: SWYFT

Important dates

Study start
2025
Primary completion
2027
Study completion
2029
First posted
Aug 11, 2025
Registry last updated
Jun 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.